RE: “Cost‐effectiveness analysis of fulvestrant versus anastrozole as first‐line treatment for hormone receptor‐positive advanced breast cancer,” by Ding H., et al.

European Journal of Cancer Care,Volume 27, Issue 2, March 2018.

Source: European Journal of Cancer Care - March 25, 2018 Category: Cancer & Oncology Source Type: research